Loading Sign Up for
Dosing
Reminders Loading

Indication

NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).

NGENLA dosing
Once-weekly NGENLA comes in multiple strengths in an easy-to-use,* prefilled, disposable pen

NGENLA pens come in 2 dosage strengths—24 mg or 60 mg. Each pen comes prefilled with the strength that is right for your child, as prescribed by his or her doctor. Every pen contains multiple weekly doses.

*NGENLA is available in prefilled pens with a low injection volume (<1 mL), a fine needle gauge, and no reconstitution required.

Explore the pen by hovering over the green spots. 

Pen cap

Dose strength
This number tells you the strength of the medication

 Dose Strength

Dose window
The injection dose is displayed in milligrams

 Dose window

Dose knob
Turn to set the dose

 Dose knob

Injection button

Medicine
The NGENLA pen is prefilled and premixed. Do not inject the medicine if it is cloudy 
or dark yellow, or if you see flakes or particles within the medicine window

 Medicine

Expiration date
Do not use NGENLA after the date stamped

 Expiration

Cartridge holder

Needle attachment
You will attach a new sterile needle here for each dose. Discard the needle after each injection

 Needle attachment

Pen Cap

Dose strength
This number tells you the strength of the medication

 Dose Strength

Medicine
The NGENLA pen is prefilled and premixed. Do not inject the medicine if it is cloudy 
or dark yellow, or if you see flakes or particles within the medicine window

 Medicine

Dose knob
Turn to set the dose

 Dose knob

Injection button

Dose window
The injection dose is displayed in milligrams

 Dose window

Expiration date
Do not use NGENLA after the date stamped

 Expiration
Cartridge holder

Needle attachment
You will attach a new sterile needle here for each dose. Discard the needle after each injection

 Needle attachment
Did you know?

Once-weekly dosing means up to ~300 fewer injections over the course of a year vs once-daily dosing. Talk to your child's doctor about whether NGENLA may be right for him or her.

~85% fewer injections

vs

1 weekly injection

7 injections per week

The following needles can be used with NGENLA pens:

Novo Nordisk®, NovoFine® Plus

Novo Nordisk®, NovoFine®

Becton Dickinson and Company, 
BD Ultra-Fine™ or BD Micro-Fine™

Pen needles are not included with the NGENLA pen shipments. You will need a prescription from your doctor to get pen needles up to a length of 8 mm from your pharmacy. Talk with your child's doctor about the right needle for him or her.

Every pen shipment comes with detailed Instructions for Use. Be sure that these instructions are followed every time a dose is given. Use a new needle for each injection. Always check the dose window to be sure that the correct dose is set.

Trademarks are owned by their respective companies.

Easy to use with a low injection volume for pediatric patients 
(<1 mL), a fine needle gauge (31G-32G), and no reconstitution required
MyNgenla Plan

After you are prescribed your dose, pen size, and treatment duration, this tool helps you to see how many pens are needed to meet your dosing needs, including when to use 2 pens.

It is not to determine treatment or calculate your NGENLA dose.

By completing the following information, you will receive a PDF to help make the most of all the medicine and minimize waste.

NGENLA storage

Store in the original carton and away from direct sunlight

Before first use, NGENLA should be stored in a refrigerator at 36°F to 46°F (2°C to 8°C). After first use of NGENLA, the pen should continue to be stored in the refrigerator for up to 28 days

Do not freeze NGENLA or expose NGENLA to heat. Do not use NGENLA if it has been frozen

Always remove and safely discard the needle after each injection. Store the NGENLA prefilled pen without an injection needle attached. Replace the cap on your prefilled pen when it is not in use

Do not use the prefilled pen for
 more than 28 days after first use. 
Do not use beyond its 
expiration date

Unused prefilled pens may be used until the expiration date printed on the carton only if the pen has been kept in the refrigerator

Important Safety Information & Use

INDICATION
NGENLA is a prescription product for the treatment of growth failure in children 3 years of age and older who do not make enough growth hormone on their own. This condition is called growth hormone deficiency (GHD).   
IMPORTANT SAFETY INFORMATION
  • Growth hormone should not be used in children after the growth plates have closed.
  • Growth hormone should not be used in children with some types of eye problems
    caused by diabetes (diabetic retinopathy).
  • Growth hormone should not be used in children who have cancer or other tumors.
  • Growth hormone should not be used in children who are critically ill because of some
    types of heart or stomach surgery, trauma, or breathing (respiratory) problems.
  • Growth hormone should not be used in children with Prader-Willi syndrome who are
    very overweight or have breathing problems including sleep apnea.
  • NGENLA should not be used by children who have had an allergic reaction to
    somatrogon-ghla or any of the ingredients in NGENLA. Look for prompt medical
    attention in case of an allergic reaction.
  • Some children have developed diabetes mellitus while taking growth hormone. Dosages
    of diabetes medicines may need to be adjusted during treatment with NGENLA.
    Children should be watched carefully if NGENLA is given along with glucocorticoid
    therapy and/or other drugs that are processed by the body in the same way.
  • In childhood cancer survivors, treatment with growth hormone may raise the likelihood
    of a new tumor, particularly some benign (non-cancerous) brain tumors. This likelihood
    may be higher in children who were treated with radiation to the brain or head. Your
    child’s health care provider will need to check your child for a return of cancer or a
    tumor.
  • Children treated with growth hormone have had increased pressure in the brain. If your
    child has headaches, eye problems, nausea (feeling like you are going to be sick), or
    vomiting, contact your child’s health care provider.
  • NGENLA may decrease thyroid hormone levels. Decreased thyroid hormone levels may
    change how well NGENLA works. Your child’s health care provider will do blood tests to
    check your child’s hormone levels.
  • Children treated with growth hormone should be checked regularly for low serum
    cortisol levels and/or the need to increase the dose of the glucocorticoids they are
    taking.
  • In children experiencing fast growth, curvature of the spine may develop or worsen. This
    is also called scoliosis. Children with scoliosis should be checked regularly to make sure
    their scoliosis does not get worse during their growth hormone therapy.
  • Use a different area on the body for each injection. This can help to avoid skin problems
    such as lumpiness or soreness.
  • Growth hormone treatment may cause serious and constant stomach (abdominal) pain.
    This could be a sign of pancreatitis. Tell your child’s health care provider if your child has
    any new stomach (abdominal) pain.
  • In studies of NGENLA in children with GHD, side effects included injection site reactions
    such as pain, swelling, rash, itching, or bleeding. Other side effects were the common
    cold, headache, fever (high temperature), low red blood cells (anemia), cough, vomiting,
    decreased thyroid hormone levels, stomach pain, rash, or throat pain.
  • A health care provider will help you with the first injection. He or she will also train you
    on how to inject NGENLA.
  • Rx only

This site is intended only for U.S. residents. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only and is not intended to replace discussions with a healthcare provider.

© 2024 Pfizer Inc. All rights reserved.
PP-SMT-USA-0408